Virginia medical cannabis sales January 2026 reached about $15.08 million, signaling a notable market moment. This January sales snapshot matters because it shows steady growth and shifting consumer preferences. Moreover, the state Cannabis Control Board dashboard made the data publicly available for the first time.
As a result, analysts and merchants can compare January performance to prior months quickly. Flower sales dominated the product mix, while concentrates and edibles also showed strong demand. The numbers reveal details about average price per gram, transactions, plants harvested, and grams packaged.
Therefore, this report will unpack trends, market growth drivers, and the consumer impact across categories. We will compare January to August through December 2025 to provide context. In addition, the piece will explain what steady six month sales mean for producers and patients.
Finally, readers will find clear takeaways and actionable insights for businesses and policy watchers. Read on to see the data points and what they mean for Virginia’s medical cannabis program.
Virginia medical cannabis sales January 2026: Volume and product mix
January 2026 recorded roughly $15.08 million in Virginia medical cannabis sales. Flower led the category with $6.55 million in sales. Concentrates followed with $5.03 million, and edibles reached about $2.55 million. The average price per gram rose to $10.20, which indicates mild upward pressure on prices. There were 126,706 transactions in January, showing steady consumer activity.
Key volume and packaging signals
- Total January sales were about $15.08M, supporting the broader medical cannabis market in Virginia.
- Flower accounted for the largest share, confirming persistent patient preference for traditional formats.
- Packaged grams in January were 1,216,287, which is lower than earlier months like August and December.
- Average price per gram increased from prior months, suggesting product mix and demand effects.
Virginia medical cannabis sales January 2026: Market drivers and period comparisons
Several market factors shaped the January results. First, steady inventory and consistent harvests kept dispensaries stocked. As a result, patients had access to a wide product assortment. Second, price movements reflect changes in mix and consumer choice. Moreover, the new Cannabis Control Authority dashboard made the data easier to analyze, and stakeholders can now track month to month trends directly via the official dashboard at Virginia Cannabis Control Authority.
Comparisons to prior months and six month trend
- January sits within a steady six month band, with August at $15.18M and December at $15.62M, which shows limited volatility.
- However, packaged grams were higher in August and December, implying seasonal packaging spikes.
- The upward shift in price per gram from September through January points to modest market growth in January 2026.
Implications for merchants, producers, and patients
- Merchants should monitor product mix because flower remains dominant yet concentrates capture large revenue shares.
- Producers may need to balance cultivation plans, given harvest counts and packaged grams trends.
- Patients benefit from stable supply, however average prices edged higher.
For regulatory context and potential policy impacts see Cannabis Regulation and Legalization Updates and for merchant-focused implications consult Virginia Adult Use Cannabis Sales Bill. Industry coverage that summarized these data is available at Virginia Medical Cannabis Sales Summary.
This analysis highlights core cannabis sales trends and market growth in January 2026. Therefore, stakeholders can use these signals to plan inventory, pricing, and policy responses.
| Month | Total sales revenue | Number of transactions | Average sale per transaction |
|---|---|---|---|
| January 2026 | $15,080,000 | 126,706 | $119.02 |
| February 2026 | Data pending | Data pending | Data pending |
| March 2026 | Data pending | Data pending | Data pending |
Virginia medical cannabis sales January 2026: Consumer impact and emerging trends
Virginia medical cannabis sales January 2026 highlight clear shifts in patient behavior. Flower led sales, so patients still prefer traditional formats. However, concentrates captured a large revenue share, which shows a move toward higher-potency products. Therefore, dispensaries and producers must adapt product mixes and stock accordingly.
Popular product types and buying patterns
- Flower accounted for $6.55 million, reinforcing base demand for smoked and vapable products.
- Concentrates generated about $5.03 million, so some patients prefer potency and convenience.
- Edibles reached $2.55 million, indicating steady interest in non inhalation options.
- Shake and trim made smaller contributions, which suggests more refined purchasing habits.
Geographic variation within Virginia
- Urban centers reported higher transaction volumes, because patient density and dispensary access concentrate in cities.
- Rural areas showed lower transaction counts but similar per sale values, implying fewer visits but larger purchases.
- Regional supply imbalances affected availability, and as a result some local prices rose above the state average.
- Therefore, local market conditions will matter more as patient access expands.
Anticipated future trends
- Expect continued demand for concentrates and ready to use formats, because convenience drives repeat purchases.
- Prices per gram may hold above recent levels as product mixes shift toward premium items.
- Producers will likely prioritize balanced cultivation to meet both flower and concentrate demand.
- Moreover, better data from the state dashboard will enable faster inventory and pricing decisions.
Takeaways for patients and industry
Patients benefit from broad product choice and steady supply. Merchants should track product mix closely and adjust stock. Producers must plan harvests to match evolving demand. Overall, January 2026 sets the tone for cautious market growth and changing consumer preferences in Virginia.
Virginia medical cannabis sales January 2026 totaled about $15.08 million, marking a steady market baseline. Over the prior six months, sales stayed in a tight range, which signals limited volatility. Flower led revenue, while concentrates and edibles captured meaningful shares. The average price per gram rose to $10.20, and transactions reached 126,706, which together show stable demand and mild upward price pressure.
Therefore, near term growth looks modest, however market dynamics favor premium formats and higher potency products. Producers face pressure to adjust cultivation and packaging. Merchants should monitor product mix and pricing to protect margins. Patients continue to benefit from broad choice and steady supply, even as per gram costs tick up.
This analysis used EMP0 alongside public Cannabis Control Board data to frame trends. As a result, readers receive research driven context and actionable signals. MyCBDAdvisor provides reliable, research driven insights for professionals and patients at MyCBDAdvisor. Moreover, ongoing dashboard releases will boost transparency and improve planning.
In short, Virginia medical cannabis sales January 2026 confirm a steady, maturing market with selective growth. Stakeholders should watch product mix, price per gram, and packaging trends in the next quarter to guide inventory and policy decisions.
Frequently Asked Questions (FAQs)
What were the key figures for Virginia medical cannabis sales January 2026?
January 2026 recorded about $15.08 million in total sales. There were 126,706 transactions. The average price per gram rose to $10.20. Flower led with $6.55 million, concentrates earned $5.03 million, and edibles reached $2.55 million. These metrics show steady demand and mild price pressure.
Why did Virginia medical cannabis sales January 2026 stay steady near $15 million?
Several factors explain the stability. First, consistent harvests kept dispensaries stocked. Second, consumer preference for flower and concentrates supported revenue. Moreover, packaging and inventory cycles caused month to month volume shifts. As a result, sales stayed in a tight range over six months.
Which product types drove consumer behavior in January 2026?
Flower dominated sales, because many patients prefer traditional formats. Concentrates showed strong growth, indicating a shift to higher potency and convenience. Edibles remained important for non inhalation patients. Therefore, merchants should stock a balanced mix to match demand.
How did January prices and transactions compare to recent months?
The average price per gram rose from earlier months. For example, prices moved up from the high nine dollar range to $10.20. Packaged grams were lower than peaks in August and December. Thus, price increases likely reflect product mix and local supply variations.
What should patients and industry expect next?
Expect cautious growth and more premium product demand. Producers will likely adjust harvest plans accordingly. Merchants should monitor inventory and pricing closely. For patients, wider choice and steady supply should continue, although per gram costs may remain slightly higher.
